Kirby McInerney LLP announced an investigation into Celcuity Inc. over potential securities fraud. The investigation concerns whether Celcuity or its senior management violated federal securities laws following the company's July 14, 2026 press release announcing FDA approval of its breast cancer therapy Revtorpyk with an anticipated commercial launch in late Q3 2026, a timeline analysts described as delayed. On July 15, 2026, Celcuity's stock fell $19.54 per share, or 17.6%, to close at $91.51 per share. No lawsuit has been filed, and the investigation is ongoing.
Celcuity LLCInvestigation for potential securities fraud over delayed Revtorpyk launch